244618-40-4

Upstream product

• 244621-33-8 4-[5-[(2R,6S)-2,6-dimethyltetrahydro-1(2H)-pyridinyl]pentyl]-2-(3-cyanophenyl)-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 244621-32-7 4-(5-bromopentyl)-2-(3-cyanophenyl)-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 244621-26-9 2-(3-cyanophenyl)-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 244621-27-0 2-(3-bromophenyl)-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 163339-67-1 methyl 2-bromo-2-(3-bromophenyl)acetate 

Downstream Products

• 244621-34-9 3-(4-[5-[(2R,6S)-2,6-dimethyltetrahydro-1(2H)-pyridinyl]pentyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)-1-N-hydroxytrifluoroacetobenzenecarboximidamide 

Relevant academic research and scientific papers

Benzoxazinoes/benzothiazinones as serine protease inhibitors

This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnornal thrombosis.

Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors

Inappropriate thrombus formation within blood vessels is the leading cause of mortality in the industrialized world. Factor Xa (FXa) is a trypsin-like serine protease that plays a key role in the blood coagulation cascade and represents an attractive targ